Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Shankar Siva on radiotherapy for primary renal cell carcinoma

Shankar Siva on radiotherapy for primary renal cell carcinoma

FromThe Lancet Oncology in conversation with


Shankar Siva on radiotherapy for primary renal cell carcinoma

FromThe Lancet Oncology in conversation with

ratings:
Length:
9 minutes
Released:
Nov 28, 2022
Format:
Podcast episode

Description

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.Read the full article:5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinomaContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Released:
Nov 28, 2022
Format:
Podcast episode

Titles in the series (100)

Editors of The Lancet Oncology and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.